医学
痰
囊性纤维化
痰
粘液
粘液纤毛清除率
支气管扩张
粘蛋白
支气管炎
祛痰药
气道
重症监护医学
哮喘
胸部理疗
慢性支气管炎
免疫学
肺
内科学
病理
肺结核
外科
药理学
替代医学
中医药
生物
生态学
出处
期刊:Respiratory Care
[American Association for Respiratory Care]
日期:2009-06-01
卷期号:54 (6): 726-732
被引量:74
标识
DOI:10.4187/002013209790983269
摘要
Although some clinicians still believe that cystic fibrosis (CF) lung disease is largely due to hypersecretion of very viscous mucus, it has never been demonstrated that there is mucus hypersecretion in CF and it is clear that there is almost no intact mucin (the principal polymeric component of normal mucus) in CF sputum. CF sputum has lower viscosity when compared to asthma or bronchitis sputa, but is highly tenacious and biochemically most closely resembles pus. Tenacity and lower viscosity lead to decreased cough clearance of infected phlegm, which is thought to induce a persistent inflammatory state in the airway, leading to bronchiectasis. There are many medications and devices either in use or under development that are meant to improve airway hygiene in CF by assisting with sputum expectoration. This paper discusses the scientific basis and potential mechanism of action for many of these interventions and briefly reviews the clinical evidence of their safety and effectiveness.
科研通智能强力驱动
Strongly Powered by AbleSci AI